BNTX
BioNTech·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BNTX
Biontech Se
A company that develops personalized immunotherapies for the treatment of cancer
Biological Technology
06/02/2008
10/10/2019
NASDAQ Stock Exchange
6,772
12-31
Depository Receipts (Ordinary Shares)
An der Goldgrube 12, D-55131 Mainz, Germany
--
BioNTech SE was established on June 2, 2008. The company combines decades of pioneering research in immunology, cutting-edge therapeutic platforms, and various patient analysis and bioinformatics tools to develop individualized immunotherapies for cancer and other diseases. The company utilizes powerful new therapeutic mechanisms, utilizes a variety of biological targets, harnesses the power of each patient's immune system, and addresses the unique molecular characteristics of each patient's underlying disease.
Company Financials
EPS
BNTX has released its 2025 Q3 earnings. EPS was reported at -0.14, versus the expected -1.12, beating expectations. The chart below visualizes how BNTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BNTX has released its 2025 Q3 earnings report, with revenue of 1.78B, reflecting a YoY change of 28.48%, and net profit of -33.68M, showing a YoY change of -115.25%. The Sankey diagram below clearly presents BNTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
